Hematology Oncology

Petros Grivas, MD, shares his treatment plan for a patient with metastatic urothelial cancer who has progressed following platinum-based chemotherapy.

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy

Geo Espinosa on Prostate Cancer for Natural Oncology Masterclass II

Michael Traub on Melanoma for Oncology Masterclass II

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. 

Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases


Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

Federal Practitioner recently talked with Dr. Adrian Weistner and Dr. Mark Roschewski of the National Institutes of Health. Both doctors will be presenting during the September 12, 2014 Lymphoma Mini-Symposium and panel discussion that kicks off this weekend’s 2014 AVAHO Meeting in Portland, Oregon

Treatments for Chronic Lymphocytic and Mantel Cell Luekemia

Roy S. Herbst MD PhD is Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center.

This is an excerpt from an interview he gave at the 2014 annual meeting of the Society for Immunotherapy of Cancer.

Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy

Oncology Learning Network